source
- Allogene CEO David Chang to step down after eight years; former Esperion chief joins PhlowLongtime Allogene chief executive David Chang announced he will leave the role at the end of June, concluding an eight‑year tenure leading the cell‑therapy developer. The company said a successor…
- Replimune to resubmit melanoma therapy RP1 to FDA after two prior rejectionsReplimune announced on Friday that it will again submit its advanced melanoma candidate, RP1, to the U.S. Food and Drug Administration for review. The company says the filing follows new discussion…